Importantly, NVB selectively kills cancer cells harboring HR deficiency (BRCA1- and BRCA2-deficiency) and potentiates the cytotoxic effect of PARP inhibition in HR-deficient cancer cells [145]. The gene discussed is BRCA2; the disease is cancer.